Do you remember the exact date of keytruda's fda approval for cancer therapy?

When was Keytruda first approved by the FDA?
Keytruda (pembrolizumab) received its initial FDA approval on September 4, 2014, for unresectable or metastatic melanoma after prior treatment.

How has the approval list grown since then?
Since 2014 the FDA has expanded Keytruda’s label to more than 30 tumor types, including non-small cell lung cancer, head and neck cancer, renal cell carcinoma, triple-negative breast cancer, and various MSI-high or TMB-high solid tumors.

Why are companies challenging this patent?
Generic and biosimilar developers are already filing patent challenges because the original composition-of-matter patents covering pembrolizumab are set to expire in 2028, opening the door for earlier market entry once exclusivity ends.

When does exclusivity expire?
The primary U.S. regulatory exclusivity for the first melanoma indication runs through 2026, but later supplemental approvals carry their own three- or five-year exclusivity periods that push full loss of exclusivity to around 2028–2030.

Can biosimilars enter before patent expiry?
Biosimilar versions cannot launch in the United States until the 12-year biologic exclusivity period and any remaining patents are resolved, so entry is unlikely before late 2028 even if litigation settles earlier.

What side effects are patients asking about?
Common questions focus on immune-related adverse events such as colitis, pneumonitis, hepatitis, and endocrinopathies, as well as infusion reactions and fatigue that can appear months after starting therapy.

How does Keytruda compare with Opdivo?
Both drugs block PD-1, but Keytruda holds broader first-line lung-cancer approvals and a slightly different dosing schedule (every three or six weeks versus Opdivo’s every two or four weeks).

Where can I find the full list of current indications and patent details?
The complete, regularly updated list of Keytruda’s FDA-approved uses and patent expiration data is available on DrugPatentWatch.com.